Back to News
Market Impact: 0.2
Satellos Granted Composition of Matter Patent for Forazapadin
Source: GlobeNewswire
Healthcare & BiotechPatents & Intellectual Property
Forazapadin has U.S. composition-of-matter protection through September 6, 2044, while advancing in Phase 2 development. The update is modestly positive for the drug’s development and intellectual-property runway; no clinical results or market reaction are reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- Up 57% since June: this AI-picked pharma stock keeps climbing
- Why is NeoGenomics stock sliding today?
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- NeoGenomics stock falls on CEO transition announcement